124 related articles for article (PubMed ID: 22248072)
21. Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology.
McCaffrey JC
Laryngoscope; 2006 Jan; 116(1):1-11. PubMed ID: 16481800
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
Frasoldati A; Pesenti M; Gallo M; Caroggio A; Salvo D; Valcavi R
Cancer; 2003 Jan; 97(1):90-6. PubMed ID: 12491509
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors of insular versus papillary/follicular thyroid carcinoma.
Falvo L; Catania A; D'Andrea V; Grilli P; D'Ercole C; De Antoni E
Am Surg; 2004 May; 70(5):461-6. PubMed ID: 15156957
[TBL] [Abstract][Full Text] [Related]
24. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
Haq M; Harmer C
Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
[TBL] [Abstract][Full Text] [Related]
25. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma.
Scheumann GF; Seeliger H; Musholt TJ; Gimm O; Wegener G; Dralle H; Hundeshagen H; Pichlmayr R
Eur J Surg; 1996 Sep; 162(9):677-84. PubMed ID: 8908447
[TBL] [Abstract][Full Text] [Related]
26. Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival.
Lin HW; Bhattacharyya N
Laryngoscope; 2010 Apr; 120(4):712-6. PubMed ID: 20205241
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
29. Treatment of locally aggressive well-differentiated thyroid cancer.
Martins AS; Melo GM; Valério JB; Langner E; Lage HT; Tincani AJ
Int Surg; 2001; 86(4):213-9. PubMed ID: 12056464
[TBL] [Abstract][Full Text] [Related]
30. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma.
Chou SJ; Chen CM; Harn HJ; Chen CJ; Liu YC
J Surg Res; 2001 Jul; 99(1):75-83. PubMed ID: 11421607
[TBL] [Abstract][Full Text] [Related]
31. Well-differentiated thyroid carcinoma: factors predicting recurrence and survival.
Lim LH; Soo KC; Chong YK; Gao F; Hong GS; Lim TH
Singapore Med J; 2002 Sep; 43(9):457-62. PubMed ID: 12568423
[TBL] [Abstract][Full Text] [Related]
32. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.
Sittel C; Eckel HE; Damm M; von Pritzbuer E; Kvasnicka HM
Laryngoscope; 2000 Jun; 110(6):1012-7. PubMed ID: 10852523
[TBL] [Abstract][Full Text] [Related]
33. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems.
Yildirim E
J Am Coll Surg; 2005 Mar; 200(3):378-92. PubMed ID: 15737848
[TBL] [Abstract][Full Text] [Related]
34. Treatment and prognostic factors of papillary thyroid microcarcinoma.
Giordano D; Gradoni P; Oretti G; Molina E; Ferri T
Clin Otolaryngol; 2010 Apr; 35(2):118-24. PubMed ID: 20500581
[TBL] [Abstract][Full Text] [Related]
35. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
36. Role of Ki-67 as a proliferative marker in lesions of thyroid.
Pujani M; Arora B; Pujani M; Singh SK; Tejwani N
Indian J Cancer; 2010; 47(3):304-7. PubMed ID: 20587907
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
38. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
39. Neuroendocrine differentiation in follicle-cell thyroid carcinoma: correlation to prognostic factors in papillary carcinoma.
Tseleni-Balafouta S; Kavantzas N; Alevizaki M; Paraskevakou H; Davaris P
J Exp Clin Cancer Res; 1998 Dec; 17(4):533-7. PubMed ID: 10089080
[TBL] [Abstract][Full Text] [Related]
40. [Differentiated thyroid cancer--staging and prognostic systems].
Dănilă R; Andriescu L; Grigorovici A; Dragomir C; Găluşcă B; Vulpoi C; Ungureanu C; Mogoş V
Rev Med Chir Soc Med Nat Iasi; 2005; 109(1):71-6. PubMed ID: 16607831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
